Analyst Expectations for Ionis Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
In the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) received 7 analyst ratings, with 4 being bullish, 1 somewhat bullish, and 2 indifferent. Over the past 3 months, 7 analysts have offered 12-month price targets for Ionis Pharmaceuticals, with an average price target of $57.86, a high of $65.00, and a low of $45.00. The average price target has increased by 56.38% over the past month.
October 23, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals received positive analyst ratings, with an increasing average price target, which could potentially boost the stock price in the short term.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings and increasing price target for Ionis Pharmaceuticals indicate a positive outlook for the company, which could potentially lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100